The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: Biological correlates of disease

AIDS

Volumn 19, Issue SUPPL. 3, 2005, Pages

  Letendre, Scott L ^a,d   Cherner, Mariana ^b   Ellis, Ronald J ^c   Marquie Beck, Jennifer ^c   Gragg, Bryan ^b   Marcotte, Thomas ^b   Heaton, Robert K ^b   McCutchan, J Allen ^a   Grant, Igor ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain; Cerebrospinal fluid; Hepatitis C; HIV; Methamphetamine

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS C ANTIBODY; METHAMPHETAMINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR II; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BRAIN INJURY; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MEMORY DISORDER; MOLECULAR MECHANICS; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGIC ASSESSMENT; SERODIAGNOSIS; STANDARDIZATION; SUBSTANCE ABUSE; UNIVERSITY HOSPITAL; VEIN PUNCTURE; VIRUS IMMUNITY;

EID: 27944472632     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000192073.18691.ff     Document Type: Article

References (28)

1. Hepatitis C. Available at http://www.who.int/csr/disease/hepatitis/ whocdscsrlyo2003/en/. Geneva: World Health Organization; 2002.
2. National Institutes of Health. Concensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
3. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999; 13:539-546.
4. Centers for Disease Control and Prevention. Cases of HIV infection and AIDS in the United States, 2002. HIV/AIDS Surveillance Report, Vol. 14. Atlanta, GA: CDC, Department of Health and Human Services; 2003.
5. Euro HIV. HIV/AIDS Surveillance in Europe: mid-year report, 2003. European Centre for the Epidemiological Monitoring of AIDS and WHO and UNAIDS Collaborating Centre on AIDS. Saint-Maurice: Institut de veille sanitaire, 2004 No. 69.
6. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
7. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16:813-828.
8. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35:433-439.
9. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9:847-854.
10. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35:440-446.
11. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004; 62:957-962.
12. Taylor-Robinson SD. Applications of magnetic resonance spectroscopy to chronic liver disease. Clin Med 2001; 1:54-60.
13. Taylor MJ, Letendre SL, Schweinsburg BC, Alhassoon OM, Brown GG, Gongvatana A, et al. Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users. J Int Neuropsychol Soc 2004; 10:110-113.
14. Caussin-Schwemling C, Schmitt C, Stoll-Keller F. Study of the infection of human blood derived monocyte/macrophages with hepatitis C virus in vitro. J Med Virol 2001; 65:14-22.
15. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76:600-608.
16. Spitzer RL, Williams JBW, Gibbon M, First M. Structured clinical interview for DSM-IV. Washington, DC: American Psychiatric Press; 1995.
17. 1993 Revised Classification System for HIV Infection and Expanded Surveillance. Case definition for AIDS among adolescents and adults. MMWR Recom Rep 1992; 41(RR-17):1-19.
18. Heaton R, Grant I, Matthews C. Comprehensive norms for an expanded Halstead-Reitan Battery: Demographic corrections, research findings, and clinical applications. Odessa: Psychological Assessment Resources, Inc; 1991.
19. Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH, et al. The HNRC 500 - neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1995; 1:231-251.
20. Heaton RK, Kirson D, Velin RA, Grant I. The utility of clinical ratings for detecting early cognitive change in HIV infection. In: Neuropsychology of HIV infection. Grant I, Martin A, editors. New York Oxford University Press; 1994. pp. 188-206.
21. Heaton RK, Miller SW, Taylor MJ, Grant I. Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults. Lutz, FL: Psychological Assessment Resources; 2004.
22. Heaton RK, Taylor MJ, Manly J. Demographic effects and use of demographically corrected norms with the WAIS III and the WMS-III. In: Clinical Interpretation of the WAIS-III and WMS-III. Edited by Tulsky D, Saklofske D, Heaton RK, et al. San Diego: Academic Press; 2003. pp.183-210.
23. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 2004; 26:307-319.
24. Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 2004; 26:759-778.
25. Maggi F, Giorgi M, Fornai C, Morrica A, Vatteroni ML, Pistello M, et al. Detection and quasispecies analysis of hepatitis C virus in the cerebrospinal fluid of infected patients. J Neurovirol 1999; 5:319-323.
26. Morsica G, Bernardi MT, Novati R, Uberti Foppa C, Castagna A, Lazzarin A. Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients. J Med Virol 1997; 53:252-254.
27. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42:679-688.
28. Ellis RJ, Moore DJ, Childers ME, Letendre S, McCutchan JA, Wolfson T, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 2002; 59:923-928.